Clinical trials keynote 158

Author: vdme

August undefined, 2024

WebJan 6, 2024 · As previously described, 15, 17 KEYNOTE-158 is an open-label, multicohort, phase II study in patients with multiple types of advanced solid tumors. Cohort D enrolled patients with endometrial carcinoma (irrespective of MSI status and excluding sarcomas and mesenchymal tumors). WebMay 20, 2014 · A Randomized Open-Label Phase III Trial of Pembrolizumab Versus Platinum Based Chemotherapy in 1L Subjects With PD-L1 Strong Metastatic Non-Small …

Efficacy of Pembrolizumab in Patients With Noncolorectal …

WebMar 1, 2024 · We report efficacy and safety outcomes for patients with MSI-H/dMMR endometrial cancer enrolled in KEYNOTE-158. Methods: Eligible patients from cohorts D … WebMar 9, 2024 · Results from the KEYNOTE-966 phase 3 trial (gemcitabine and cisplatin plus pembrolizumab or placebo; NCT04003636) and the EORTC1607 phase 2 trial (gemcitabine and cisplatin plus pembrolizumab; NCT03260712) in the same setting are awaited, along with results from the IMMUNOBIL PRODIGE 57 phase 2 study (NCT03704480) of … bootswerft marcel gasser

Advanced Tumor Mutational Burden-High (TMB-H) Cancers KEYNOTE …

WebJun 16, 2024 · Jun 16, 2024. Lisa Astor. "KEYNOTE-158 has confirmed clinical activity of pembrolizumab in tumors harboring a TMB ≥10 across a variety of solid tumors including anal, biliary, cervical, endometrial, mesothelioma, neuroendocrine, salivary, small cell lung, thyroid, and vulvar cancers." The FDA has approved pembrolizumab (Keytruda) for the ... Web1 day ago · Merck has the industry’s largest immuno-oncology clinical research program. There are currently more than 1,600 trials studying KEYTRUDA across a wide variety of cancers and treatment settings. ... In KEYNOTE-158 and KEYNOTE-164, adverse reactions occurring in patients with MSI-H or dMMR cancer were similar to those occurring in … WebFeb 4, 2014 · This study will assess the efficacy and safety of pembrolizumab (MK-3475) administered to participants with incurable advanced biomarker-positive solid tumors that … hatton christmas

PubMed Central (PMC)

WebClinicalTrials.gov is a database of privately and publicly funded clinical studies conducted around the world. Explore 448,116 research studies in all 50 states and in 221 countries. See listed clinical studies related to the coronavirus disease (COVID-19) ClinicalTrials.gov is a resource provided by the U.S. National Library of Medicine. WebApr 13, 2024 · One thousand and seventy-three patients with advanced solid tumors were enrolled in the phase II KEYNOTE-158 study, 76% of whom were eligible for TMB status evaluation . Patients with tumor mutation burden-high (TMB-H) had a significantly higher ORR (29% vs. 6%) than other patients when using a threshold of 10 muts/Mb. ... Phase … bootswerft rudolf bodmanWebApr 3, 2024 · PURPOSE KEYNOTE-158 (ClinicalTrials.gov identiﬁer: NCT02628067) is a phase II basket study investigating the antitumor activity and safety of pembrolizumab in … boots westburn road

"WebAug 8, 2024 · The results of this study in Japanese patients were consistent with those of the phase 3 KEYNOTE-010 trial. Treatment with pembrolizumab at a dose of 10 mg/kg every 3 weeks for up to 2 years led to an ORR of 27% among patients with a PD-L1 TPS of at least 50% and of 22% among those with a TPS of at least 1%. " - Clinical trials keynote 158

Clinical trials keynote 158

Frontiers The efficacy and safety of anti-PD-1/PD-L1 in treatment …

WebFeb 1, 2024 · Thus far, some pivotal trials, including Keynote 028, Keynote 158 and Checkmate 358, have indicated established clinical benefit of PD-1/PD-L1 inhibitors in cervical cancer. In light of these data, the FDA has approved pembrolizumab for patients with recurrent or metastatic cervical cancer with disease progression during or after … WebPubMed Central (PMC)

Did you know?

WebJan 6, 2024 · We report efficacy and safety outcomes for patients with MSI-H/dMMR endometrial cancer enrolled in KEYNOTE-158. METHODS Eligible patients from cohorts … WebSep 1, 2024 · KEYNOTE-158 used a cutoff of ≥10 Mut/Mb using the FoundationOne CDx panel to define TMB-H. This cutoff appeared to identify patients in the dataset with a likelihood of responding to pembrolizumab therapy; however, occasional responses were also reported in the non–TMB-H group in this trial.

WebApr 6, 2024 · Key Points. Question Does first-line nivolumab plus ipilimumab provide clinical benefit vs nivolumab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)?. Findings In this randomized clinical trial of 425 adults with platinum-refractory or platinum-eligible R/M SCCHN, the primary end …

WebApr 7, 2024 · In KEYNOTE-158 and KEYNOTE-164, adverse reactions occurring in patients with MSI-H or dMMR cancer were similar to those occurring in patients with other solid tumors who received KEYTRUDA as a single agent. ... Across clinical trials in 799 patients with DTC, RCC, and HCC, grade 3 or higher cardiac dysfunction occurred in 3% of … WebJun 10, 2024 · Purpose: KEYNOTE-158 ( ClinicalTrials.gov identifier: NCT02628067) is a phase II basket study investigating the antitumor activity and safety of pembrolizumab in …

WebApr 14, 2024 · A total of 20 clinical trials involving 2,321 glioma patients were included in this meta-analysis to evaluate the efficacy and safety of PD-1/PD-1 inhibitors in the treatment of glioma. To our surprise, compared to control arm, anti-PD-1/PD-L1 therapy didn’t prolong OS and PFS but shortened it in Phase III RCTs meta-analysis.

WebKEYNOTE⁠-⁠158 enrolled and evaluated the efficacy of 90 patients with unresectable or metastatic MSI⁠-⁠H or dMMR endometrial carcinoma who received at least 1 dose of … boots west bridgefordWebApr 3, 2024 · KEYNOTE-158 ( ClinicalTrials.gov identifier: NCT02628067) is a phase II basket study investigating the antitumor activity and safety of pembrolizumab in multiple cancer types. We present interim results from … boots were made for walking nancy sinatraWebJun 23, 2024 · KEYNOTE-158 is an example of such biomarker driven clinical trials that ended up with two tumor agnostic indications in regulatory approvals, one for microsatellite instability (MSI)-high solid tumors and the other is for tissue mutational burden (TMB)- high solid tumors [21, 69]. All the existing studies leading to tumor agnostic approval are ... hatton churchWebApr 6, 2024 · Merck has the industry's largest immuno-oncology clinical research program. There are currently more than 1,600 trials studying KEYTRUDA across a wide variety of cancers and treatment settings. ... In KEYNOTE-158 and KEYNOTE-164, adverse reactions occurring in patients with MSI-H or dMMR cancer were similar to those occurring in … hatton church lincolnshireWebJan 13, 2024 · In the non-randomised, open-label, multicohort, phase II KEYNOTE-158 study of pembrolizumab in multiple types of advanced rare cancers, pembrolizumab … hatton church of christ town creek alWebMay 1, 2024 · KEYNOTE-158 (ClinicalTrials.gov identifier: NCT02628067) investigated the efficacy and safety of pembrolizumab across multiple cancers. We present results from patients with previously treated advanced well-differentiated neuroendocrine tumors (NET). Patients and Methods: boots westbury opening timesWebSep 18, 2024 · In the phase 2 KEYNOTE-158 trial of pembrolizumab monotherapy for previously treated metastatic or unresectable cervical cancer, all responses were … boots westcroft address